FIELD: chemistry.
SUBSTANCE: present invention relates to a novel crystal of a lobaplatin compound (crystalline form A). Crystal is characterised by two molecules of crystal water, which are in a crystal structure. Also disclosed are a method for preparation of crystal A, novel lobaplatin crystals, which are crystalline forms B and F, methods for preparation thereof, a pharmaceutical composition and use of said novel crystals for preparation of anticancer drugs.
EFFECT: in comparison with existing lobaplatin and lobaplatin trihydrate, lobaplatin crystals A, B and F have better stability and solubility and can be more effectively used in the treatment of cancer forms such as breast cancer, small cell lung cancer or chronic myeloid leukemia.
41 cl, 10 dwg, 15 tbl, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS, STIMULATING HAIR GROWING | 2005 |
|
RU2342384C2 |
| SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE, AS WELL AS TARTRATE AND CRYSTALLINE FORMS THEREOF | 2005 |
|
RU2417986C2 |
| POLYMORPHOUS AND AMORPHOUS FORMS OF {2-FLUORINE-5-[3-((E)-2-PYRIDINE-2-ILVINYL)-1N-INDAZOLE-6-ILAMINE]PHENYL}AMIDE 2, 5-DIMETHYL-2N-PYRAZOLE-3-CARBONIC ACID | 2005 |
|
RU2324692C1 |
| SOLID FORMS OF NEMATOCIDAL SULFONAMIDES | 2012 |
|
RU2615139C2 |
| CRYSTAL COMPOUNDS | 2016 |
|
RU2789672C2 |
| MULTICOMPONENT CRYSTALS COMPRISING DASATINIB AND SELECTED COCRYSTAL FORMERS | 2013 |
|
RU2650524C2 |
| SYK INHIBITOR SALT AND CRYSTALLINE FORM THEREOF | 2019 |
|
RU2818103C2 |
| ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR TREATMENT OF BCL-2 PROTEIN RELATED DISEASES | 2010 |
|
RU2551376C2 |
| CRYSTALLINE FORM OF COMPOUND SUPPRESSING PROTEIN KINASE ACTIVITY AND THE USE THEREOF | 2017 |
|
RU2744264C2 |
| MULTICOMPONENT CRYSTALLINE SYSTEM COMPRISING NILOTINIB AND SELECTED CO-CRYSTAL FORMERS | 2013 |
|
RU2652121C2 |
